The PIPE removes near-term financing overhang and funds a key catalyst (SOTERIA trial initiation). The no-resale-registration stance limits immediate overhang. Monitor for SOTERIA enrollment updates and any subsequent capital needs beyond Q2 2027.
Price Chart
Executive Summary
Polaryx Therapeutics closed a $10M PIPE financing on May 28, 2026, issuing 2,502,696 shares (~5.3% dilution) at an average price of ~$4.00/share. Proceeds will fund the Phase 2 SOTERIA basket trial and extend the cash runway through Q2 2027. The dilutive raise is a necessary capital event for a pre-revenue clinical-stage biotech, but the 5.3% dilution is modest and the company explicitly stated it will not file a resale registration statement, limiting near-term overhang.
Key Financial Metrics
Key Facts
- Closed $10M PIPE financing on May 28, 2026 with ~35 investors including largest holder MStone Partners Healthcare ($360K participation).
- Issued 2,502,696 shares at a weighted average price of ~$4.00/share, representing ~5.3% dilution of pre-offering outstanding shares.
- Net proceeds to fund Phase 2 SOTERIA basket trial (PLX-200) and for working capital; expected to extend operating runway through Q2 2027.
- Company will not file a resale registration statement for the PIPE shares, keeping them restricted and reducing immediate selling pressure.
- SOTERIA trial has FDA Fast Track Designation for all four planned indications; trial initiation planned for H2 2026.
Financial Impact
$10M gross proceeds at ~$4.00/share; 5.3% dilution to existing shareholders.
Risk Factors
- Clinical-stage biotech with no approved products; SOTERIA trial may fail to show efficacy or safety.
- Cash runway only through Q2 2027; additional dilutive financing likely needed before data readouts.
- Shares are restricted but could be sold under Rule 144 after holding period, creating future overhang.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-062155 |
| Document: ea029169201ex10-1.htm | 0001213900-26-062155 |
| Document: ea029169201ex99-1.htm | 0001213900-26-062155 |
| Document: 0001213900-26-062155-index-headers.html | 0001213900-26-062155 |
| Document: 0001213900-26-062155-index.html | 0001213900-26-062155 |
| Document: 0001213900-26-062155.txt | 0001213900-26-062155 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 17, 2026 14w ago | 8-K | $2.28 $2.01 | ▼ −11.84% | ▼ −16.53% | $1.88 (−17.54%) |
May 28, 2026 21w ago | 8-K | $3.27 $1.87 | ▼ −42.81% | ▼ −44.00% | $1.88 (−42.51%) |
May 28, 2026 21w ago | Press Release | $3.05 $2.07 | ▼ −32.13% | ▼ −33.87% | $1.88 (−38.36%) |
Apr 21, 2026 27w ago | Press Release | $5.27 $2.31 | ▼ −56.17% | ▼ −63.07% | $1.88 (−64.33%) |
Mar 17, 2026 32w ago | Press Release | $5.63 $2.28 | ▼ −59.50% | ▼ −69.36% | $1.88 (−66.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers